Pharmafile Logo
Pharmafocus logo
Advanced Search

Press release

Showing 15 posts of 581 posts found.

New technology to “unlock” NHS records to revolutionise how we take medicine

January 11, 2023
Business Services

London, UK – New technology which can “unlock” medication records has been awarded £1m in fresh funding by Innovate UK.

News
Press release

STORM Therapeutics Expands R&D Leadership Team

January 10, 2023
Business Services

10 January 2023, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the clinical stage biotechnology company discovering and developing novel small molecule …

News
Press release

Positive Initial Data Analysis in POLB 001 LPS Challenge Trial

January 9, 2023
Business Services

9 January 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a leading infectious disease focused biopharmaceutical …

News
Press release

Novo Holdings invests in proteomics technology company, Evosep

January 9, 2023
Business Services

The proceeds from the investment by Novo Holdings will be used to advance clinical applications of proteomics enabled by Evosep’s …

News
Press release

Transgene Receives Approval to Start a Phase I Trial of TG6050, a Novel IL-12-Armed Oncolytic Virus Given by Intravenous Administration

January 6, 2023
Business Services

Strasbourg, France, January 6, 2023, 7:30 a.m.

News
Press release

Synaffix Enters License Agreement with Amgen to Build Next Generation ADCs

January 5, 2023
Medical Communications

AMSTERDAM, THE NETHERLANDS, 5 January 2023 — Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology for …

News
Press release

Nouscom Announces Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate NOUS-209 in combination with KEYTRUDA® (pembrolizumab) in a Phase 2 Randomized Trials in dMMR/MSI-High Metastatic Colorectal Cancer

January 5, 2023
Business Services

BASEL, Switzerland – 5th January 2023 – Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized immunotherapies, today announced …

News
Press release

iOnctura provides development update on first-in-class semi-allosteric PI3Kδ inhibitor program

January 5, 2023
Business Services

Geneva, Switzerland and Amsterdam, The Netherlands, 5 January – iOnctura, a clinical-stage biotech developing selective cancer therapies against targets that …

News
Press release

Adcendo ApS Announces License Agreement with Duality Biologics on Next-generation ADC Platform

January 5, 2023
Business Services

Copenhagen, Denmark, January 5, 2023 – Adcendo ApS (“Adcendo”), a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) …

News
Press release

Sosei Heptares Notes its Partner Tempero Bio has Received FDA Clearance to Advance Clinical Development of TMP-301 for Treatment of Alcohol and Substance Use Disorders

January 5, 2023
Business Services

Tokyo, Japan and Cambridge, UK, 5 January 2023 – Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in …

News
Press release

Hummingbird Bioscience and Synaffix Enter License Agreement to Develop a Next Generation Antibody Drug Conjugate (ADC) Program

January 4, 2023
Business Services

Amsterdam and San Francisco / Houston / Singapore, 4 January 2023 — Synaffix B.V.

News
Press release

ISA Pharmaceuticals and Cancer Focus Fund Announce $5 Million Investment to Support First-in-Human Trial of ISA’s Novel Immunotherapy ISA103 in Uveal Melanoma

January 4, 2023
Business Services

Oegstgeest, Netherlands and Houston, Texas, January 4, 2023 – ISA Pharmaceuticals, B.V., a clinical stage biotech company developing immunotherapies to …

News
Press release

Actimed Therapeutics successfully closes second tranche of £10m seed financing to progress pipeline for treatment of cancer cachexia and other muscle wasting disorders

January 4, 2023
Business Services

London, UK – 4 January 2023. Actimed Therapeutics Ltd, a UK based clinical stage specialty pharmaceutical company focused on bringing …

News
Press release

Newron announces striking six-month interim results from its exploratory clinical trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia

January 3, 2023
Business Services

Milan, Italy, Jan. 3, 2023, 07:00 am CET – Newron Pharmaceuticals S.p.A.

News
Press release

Janssen Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of Talquetamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

January 3, 2023
Business Services

BEERSE, BELGIUM, 3 January 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a …

News
Press release
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025